Open AccessInteractions between cardiology and oncology drugs in precision cardio-oncology
Author(s) -
Sailaja Kamaraju,
Meera Mohan,
Svetlana Zaharova,
Brianna Wallace,
Joseph McGraw,
James Lokken,
John F. Tierney,
Elizabeth Weil,
Olubadewa A. Fatunde,
Sherry-Ann Brown
Publication year - 2021
Publication title -
clinical science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.91
H-Index - 138
eISSN - 1470-8736
pISSN - 0143-5221
DOI - 10.1042/cs20200309
Subject(s) - medicine , cardiotoxicity , subspecialty , precision medicine , cancer , intensive care medicine , disease , pharmacogenomics , drug , oncology , pharmacology , chemotherapy , pathology
Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.